Savara Inc.: Savara Awarded Promising Innovative Medicine (PIM) Designation in the United Kingdom (UK) for Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
PIM Designation Recognizes Molgramostim as a Promising Candidate for the UK Early Access to Medicines Scheme (EAMS) A Program that Aims to Give Patients with Life Threatening or Seriously Debilitating
Source: finanznachrichten.de